CSL Limited
45 Poplar Road Parkville
Victoria 3052 Australia

T +613 9389 1911
F +613 9389 1434
www.csl.com.au

ASX Announcement

For immediate release

24 May 2016

FLUCELVAX QUADRIVALENT™ (Influenza Vaccine) – FDA approval

CSL Limited (ASX:CSL; USOTC:CSLLY) - CSL today announced that the US Food and Drug Administration (***FDA***) has approved Seqirus' FLUCELVAX QUADRIVALENT™ (Influenza Vaccine), the first four-strain, cell culture-derived, inactivated seasonal influenza vaccine for people aged four years and older. FLUCELVAX QUADRIVALENT helps protect against the two influenza A viruses and two B viruses recommended by the World Health Organization (***WHO***) and the FDA for the current influenza season.

"As the first and only cell culture-derived seasonal influenza vaccine in the US to offer four-strain flu protection for people aged four years and older, FLUCELVAX QUADRIVALENT will provide healthcare providers and their patients with an important option to further broaden their influenza coverage," said Gordon Naylor, President, Seqirus. "We are pleased to offer FLUCELVAX QUADRIVALENT, which is produced at our full-scale cell culture influenza vaccine manufacturing facility in Holly Springs, North Carolina, to our valued customers during the 2016-2017 US flu season."

FLUCELVAX QUADRIVALENT is produced using the same full-scale cell culture manufacturing technology as its predecessor FLUCELVAX® (Influenza Vaccine), which allows the potential for rapidly increased production of flu shots in response to outbreaks or pandemic. Cell culture technology does not depend on eggs for manufacturing, and the vaccine is produced in sterile bioreactors. The change to using cells rather than eggs represented the first major development in influenza vaccine manufacturing technology since vaccine production began in the 1930s.

About Seasonal Influenza

Influenza is a common, highly contagious infectious disease that can cause severe illness and life-threatening complications in many people. Because transmission to others may occur one day before symptoms develop and up to five to seven days after becoming sick, the disease can be easily transmitted to others. Influenza can lead to clinical symptoms varying from mild to moderate respiratory illness to severe complications, hospitalization and in some cases death. On average, more than 200,000 people are hospitalized due to influenza-related complications in the US each year.

About FLUCELVAX QUADRIVALENT

FLUCELVAX QUADRIVALENT is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLUCELVAX QUADRIVALENT is approved for use in persons four years of age and older.

About CSL

CSL is a leading global biotherapeutics company with a dynamic portfolio of life-saving innovations, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL — including our two businesses CSL Behring and Seqirus — operates in over 30 countries with more than 16,000 employees. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For more information, please visit www.csl.com.au.

For further information, please contact:

Investors:
Mark Dehring
Head of Investor Relations
CSL Limited
Phone: +613 9389 3407
Email: mark.dehring@csl.com.au

Media:
Sharon McHale
Head of Public Affairs
CSL Limited
Mobile +61 409 978 314
Email: sharon.mchale@csl.com.au